Hale Therapeutics

Hale Therapeutics

Early Stage

Proprietary medical vaporizer and mobile application to help smokers quit nicotine more easily

Proprietary medical vaporizer and mobile application to help smokers quit nicotine more easily


Raised to Date: Raised: $26,500

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Convertible Note



SEC Filing Type

RegCF / RegD 506(c)    Open SEC Filing

Valuation Cap




Rolling Commitments ($USD)

Not Funded
Reporting Date


Days Remaining
Not Funded
% of Min. Goal
Not Funded
% of Max. Goal
Not Funded
Likelihood of Max
Not Funded
Avg. Daily Raise


Not Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Philadelphia, Pennsylvania

Business Type

High Growth

Hale Therapeutics, with a valuation of $15 million, is raising funds on SeedInvest. The company has developed its proprietary medical vaporizer and mobile app that helps smokers quit nicotine more easily. The dual-capsule solution of Hale Therapeutics is disrupting current nicotine replacement therapies and is designed to wean people off of nicotine with minimum withdrawal symptoms gradually. Josh Israel founded Hale Therapeutics in July 2018. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1,070,000. The campaign proceeds will be used for preclinical testing, clinical trials, and GMP manufacturing setup.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 02/28/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Founder Profile

Hale Therapeutics Founder Josh Israel Is Determined to Help Smokers Quit

Once upon a time, cigarette companies marketed their products with the promises of healing properties and the trustworthy faces of dentists, babies, and Santa Claus. Today the health consequences of smoking tobacco are well known, and most smokers want to quit. But despite modern advancements in medicine and technology, quitting success rates remain dismally low.

Hale Therapeutics is on a mission to help smokers quit with a new method: smoking. The company has created a patented dual-capsule vaporizer that will gradually ease smokers off of nicotine with steps that may be familiar to them. We reached out to co-founder and CEO Josh Israel to learn about the origin of Hale Therapeutics and where the company might go from here.

Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.

Read Founder Interview

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Hale Therapeutics on SeedInvest 2022
Platform: SeedInvest
Security Type: Convertible Note
Valuation: $15,000,000

Follow company

Follow Hale Therapeutics on SeedInvest 2022

Buy Hale Therapeutics's Deal Report

Warning: according to the close date for this deal, Hale Therapeutics may no longer be accepting investments.

Hale Therapeutics Deal Report

Get KingsCrowd’s comprehensive report on Hale Therapeutics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Hale Therapeutics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Hale Therapeutics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge